secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2024-07-15T23:59:59+00:00
Accession:  0001099800-24-000066
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Lifesciences exercises option to acquire Innovalve for ~$300M cash
--------------------------------------------------------------------------

- Edwards Lifesciences (EW) acquires early-stage TMVR company Innovalve Bio Medical Ltd.
- Consideration of ~$300M in cash; expected closing by end of 2024.
- Innovalve to join TMTT product group; initial investment made in 2017.
- Edwards' SAPIEN M3 TMVR system on track for European approval by end of 2025.
- Acquisition aims to expand treatable mitral valve population with combined platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000066/0001099800-24-000066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000066/ew-20240715.htm
  HTML page:      https://secwatch.observer/filing/0001099800-24-000066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer